Drug Discovery & Development - January 05, 2011
BERLIN (AP) - Germany's Bayer AG says it has submitted an application seeking authorization to sell its new anti-clotting drug Rivaroxaban within the European Union.
The company said it is seeking approval from the European Medicines Agency to sell the blood thinner to prevent strokes in people with a common heart rhythm problem and treat deep vein thrombosis.
Rivaroxaban is being developed by Bayer HealthCare and U.S. pharmaceutical company Johnson & Johnson, based in New Brunswick, New Jersey.
In the U.S., the drug would be sold by Johnson & Johnson's Ortho-McNeil division. Approval from the U.S. Food and Drug Administration is pending.
Bayer is responsible for marketing outside the U.S.
Date: January 5, 2010
Source: Associated Press
The company said it is seeking approval from the European Medicines Agency to sell the blood thinner to prevent strokes in people with a common heart rhythm problem and treat deep vein thrombosis.
Rivaroxaban is being developed by Bayer HealthCare and U.S. pharmaceutical company Johnson & Johnson, based in New Brunswick, New Jersey.
In the U.S., the drug would be sold by Johnson & Johnson's Ortho-McNeil division. Approval from the U.S. Food and Drug Administration is pending.
Bayer is responsible for marketing outside the U.S.
Date: January 5, 2010
Source: Associated Press
No hay comentarios:
Publicar un comentario